PIM2 and non-Hodgkin lymphoma: Two of the 23 MM essential genes, PIM2 and IKBKB, are catalogued as targets for six therapies across 19 disease categories: nine in the context of cancer including MM, non-Hodgkin lymphoma, and acute myeloid leukaemia (Supplementary Table 6).